PDCD1 and cancer: Therefore, speculating that inhibitors of METTL3, IGF2BP, FTO, and ALKBH may be promising targets for cancer therapy is reasonable, and moreover, combination of these inhibitors with PD-1 inhibitors may enhance the efficacy of anti-PD-1 therapy to overcome drug resistance.